Home › Colorectal Cancer › Rhode Island › Providence
Colorectal Cancer clinical trials in Providence, RI
4 studies for Colorectal Cancer are looking for participants at sites in and around Providence (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RecruitingPhase 1
- Rhode Island Hospital, Providence
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
RecruitingPhase 3
- Clinical Study Site, Providence
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RecruitingPhase 1/2
- Brown University Health Cancer Institute, Providence
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecruitingPhase 1
- Rhode Island Hospital, Providence
About Colorectal Cancer
Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, when treatment is most effective.
More about Colorectal Cancer on MedlinePlus
Colorectal Cancer trials in other cities
- Houston, TX102 studies
- New York City, NY77 studies
- Nashville, TN69 studies
- Boston, MA63 studies
- Los Angeles, CA59 studies
- Arlington, VA52 studies
- St. Louis, MO50 studies
- San Antonio, TX46 studies
- Philadelphia, PA44 studies
- Grand Rapids, MI40 studies
- Baldwin Park, CA38 studies
- Seattle, WA34 studies
Other studies in Providence
- Ovarian Cancer15 studies
- Endometrial Cancer14 studies
- Obesity14 studies
- Non-Small Cell Lung Cancer12 studies
- Cancer (all types)12 studies
- Crohn's Disease12 studies
- Ulcerative Colitis11 studies
- Breast Cancer11 studies
- Acute Myeloid Leukemia10 studies
- Metastatic Cancer9 studies
- Overweight9 studies
- Alzheimer's Disease8 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.